logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.
    1. Home
    2. Class
    3. Retinoid

    Retinoid class drugs

    FiltersReset Filters
    14 results

    • aklief

      (trifarotene)
      Galderma Laboratories, L.P.
      Usage: AKLIEF Cream is a retinoid indicated for the topical treatment of acne vulgaris in patients aged 9 years and older.

    • altreno

      (tretinoin)
      Bausch Health US, LLC
      Usage: ALTRENO® (tretinoin) lotion, 0.05% is indicated for the topical treatment of acne vulgaris in patients aged 9 years and older.

    • arazlo

      (tazarotene)
      Bausch Health US, LLC
      Usage: ARAZLO® (tazarotene) lotion, 0.045% is indicated for the topical treatment of acne vulgaris in patients aged 9 and older.

    • duobrii

      (halobetasol propionate and tazarotene)
      Bausch Health US, LLC
      Usage: DUOBRII® (halobetasol propionate and tazarotene) Lotion is indicated for the topical treatment of plaque psoriasis in adults.

    • epiduo

      (adapalene and benzoyl peroxide)
      Galderma Laboratories, L.P.
      Usage: EPIDUO gel is indicated for the topical treatment of acne vulgaris in patients aged 9 years and older.

    • fabior

      (tazarotene)
      Mayne Pharma
      Usage: FABIOR® (tazarotene) Foam, 0.1% is indicated for the topical treatment of acne vulgaris in patients aged 12 years and older.

    • panretin

      (alitretinoin)
      Concordia Pharmaceuticals Inc.
      Usage: Panretin® gel is indicated for the topical treatment of cutaneous lesions in patients with AIDS-related Kaposi’s sarcoma. It is not suitable for cases requiring systemic anti-KS therapy or where significant symptoms are present.

    • retin-a micro

      (Tretinoin)
      Bausch Health US LLC
      Usage: Retin-A Micro® is a retinoid indicated for topical use in the treatment of acne vulgaris.

    • sohonos

      (palovarotene)
      Ipsen Biopharmaceuticals, Inc.
      Usage: SOHONOS is indicated for reducing the volume of new heterotopic ossification in adults and pediatric patients with fibrodysplasia ossificans progressiva (FOP), specifically in females aged 8 years and older and males aged 10 years and older.

    • targretin

      (bexarotene)
      Bausch Health US, LLC
      Usage: Targretin (bexarotene) gel 1% is indicated for the topical treatment of cutaneous lesions in patients with Stage IA and IB CTCL, specifically for those with refractory or persistent disease or who have not tolerated other therapies.